Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries

Abstract

BackgroundThe amount of resources, particularly prepaid resources, available for health can affect access to health care and health outcomes. Although health spending tends to increase with economic development, tremendous variation exists among health financing systems. Estimates of future spending can be beneficial for policy makers and planners, and can identify financing gaps. In this study, we estimate future gross domestic product (GDP), all-sector government spending, and health spending disaggregated by source, and we compare expected future spending to potential future spending.MethodsWe extracted GDP, government spending in 184 countries from 1980–2015, and health spend data from 1995–2014. We used a series of ensemble models to estimate future GDP, all-sector government spending, development assistance for health, and government, out-of-pocket, and prepaid private health spending through 2040. We used frontier analyses to identify patterns exhibited by the countries that dedicate the most funding to health, and used these frontiers to estimate potential health spending for each low-income or middle-income country. All estimates are inflation and purchasing power adjusted.FindingsWe estimated that global spending on health will increase from US$9·21 trillion in 2014 to $24·24 trillion (uncertainty interval [UI] 20·47–29·72) in 2040. We expect per capita health spending to increase fastest in upper-middle-income countries, at 5·3% (UI 4·1–6·8) per year. This growth is driven by continued growth in GDP, government spending, and government health spending. Lower-middle income countries are expected to grow at 4·2% (3·8–4·9). High-income countries are expected to grow at 2·1% (UI 1·8–2·4) and low-income countries are expected to grow at 1·8% (1·0–2·8). Despite this growth, health spending per capita in low-income countries is expected to remain low, at $154 (UI 133–181) per capita in 2030 and $195 (157–258) per capita in 2040. Increases in national health spending to reach the level of the countries who spend the most on health, relative to their level of economic development, would mean $321 (157–258) per capita was available for health in 2040 in low-income countries.InterpretationHealth spending is associated with economic development but past trends and relationships suggest that spending will remain variable, and low in some low-resource settings. Policy change could lead to increased health spending, although for the poorest countries external support might remain essential.FundingBill & Melinda Gates Foundation.

Deconstructing the Financialization of Healthcare

“…Health of populations is considered a prerequisite for sustainable development, and US$ 371 billion annually is estimated as necessary to achieve targets for SDG 3 alone, to ‘ensure healthy lives and promote well‐being’ (Stenberg et al., ). While the aspirations set out in the targets for Goal 3 require many promotion and prevention actions in spheres well beyond healthcare, it is healthcare industries that are experiencing considerable growth (Deloitte, ) as global per capita spending on health is expected to increase 50 per cent by 2030, with much of the growth concentrated in middle‐income countries (Dieleman et al., ).…”

Medicines prescribing pattern in northern Ghana: does it comply with WHO recommendations for prescribing indicators?

“…It is estimated that, as high as 25 to 70% of the entire health budgets of developing countries are spent on medicines, despite the limited budgetary allocations to health in these countries, whereas, about 10% of health expenditure in the developed economies is spent on medicines (Dielman, 2017). Inappropriate prescribing and use of antimicrobial agents have led to a swift increase in antibiotic resistance globally, leading to increased significant morbidity and mortality (Li and Webster, 2018).…”

How should HIV resources be allocated? Lessons learnt from applying Optima HIV in 23 countries

“…Within health economics, a response is described as allocatively efficient if funds are allocated across different HIV interventions and delivery modalities in the way that leads to the best possible epidemic outcomes given any relevant constraints. This is particularly important in the current epidemiological and funding context. Since 2002, an estimated US$80.3 billion in development assistance for HIV programmes has been disbursed in over 100 lower‐income countries .…”